A series of 3-methylenamino-4(3H)-quinazolone derivatives were synthesized by imine formation reactions of 3-amino-6-chloro-2-phenyl-4(3H)-quinazolone with various substituted aromatic aldehydes at 80 °C for 1–3 hours using the reflux method. Twenty 3-methylenamino-4(3H)-quinazolone derivatives were synthesized with good to excellent yields (66 to 90%). Compound 5 (2-chloro-6-fluorobenzylidene) exhibited good cytotoxic activity against the RD cell line with an IC50value of 14.65 μM but exhibited weak cytotoxic activity against the MDA-MB-231 cell line (IC50= 147.70 μM) compared to the reference drug paclitaxel (PTX, IC50RD = 0.58 μM and IC50MDA-MB-231 = 0.04 μM). Meanwhile, compounds 6 (benzo[d][1,3]dioxol-5-ylmethylene) and 7 (4-bromo-2-hydroxybenzylidene) showed good cytotoxic activity against MDA-MB-231 with IC50values of 10.62 and 8.79 μM, respectively. However, these compounds showed weak cytotoxic activity against the RD cell line (IC50= 50–55 μM). In particular, potential compounds 5, 6, and 7 exhibited weak cytotoxic activity against the normal cell line LLC-PK1 (IC50= 34.82–60.18 μM) compared to the highly toxic agent PTX (IC50= 1.31 μM). Furthermore, compounds 5, 6, and 7 showed strong interactions with the EGFR target with binding affinities of −9.6, −10.1, and −9.8 kcal mol−1, respectively, compared to reference drug Gefitinib (−7.8 kcal mol−1). Thein silicoADMET results suggested that these potent derivatives possess a good ADMET profile. Therefore, these three compounds are potential candidates for novel cancer drug development, as demonstrated byin vitroandin silicostudies.

Twenty 3-methylenamino-4(3H)-quinazolone derivatives were synthesizedviaimine formation. Compounds 5, 6, and 7 showed potent cytotoxicity against RD and MDA-MB-231, low toxicity to normal cells, and strong EGFR binding, with good ADMET profiles.

Heterocycles play a very important role in new drug development.1–5Quinazoline (or 1,3-diazanaphthalene/benzo[d]pyrimidine) is a double cyclic compound consisting of a pyrimidine ring condensed at position 5, 6 with a benzene ring. This scaffold is the pharmacophore nucleus present in many compounds with potential pharmacological effects, widely used in the pharmaceutical field.1Among quinazoline derivatives, the group of 4(3H)-quinazolone derivatives (or 4(3H)-quinazolinone) has received the most research attention, with many potential compounds having been synthesized and tested for biological activity.2Many studies have demonstrated that the quinazolone nucleus has diverse biological activities, such as antibacterial,6–8antifungal,9anticancer,10–15analgesic,16–18anti-inflammatory,16,18antiviral,19,20antituberculosis,21antioxidant,22,23and antihypertensive.24In particular, many 4(3H)-quinazolone derivatives have been developed into therapeutic drugs such as febrifugine (antimalarial), albaconazole (antifungal), balaglitazone (antihyperglycemic), diproqualone (GABAergic), afloqualone (GABAergic), fenquizone (diuretic), quinethazone (antihypertensive), halofuginone (antiprotozoal), and raltitrexed (anticancer) (Fig. 1).

In many research works, scientists have made efforts to improve the reactions to form 4(3H)-quinazolone heterocycles to evaluate or screen biological activities and discover active mechanisms. Many derivatives have shown potent anticancer properties.25–34In addition, the 4(3H)-quinazolone nucleus has many sites that can attach different substituents, especially at positions 2, 3, 6, and 7, from which many new derivatives with good biological effects can be created.25–34Moreover, theN-methylenamino substituent at position 3 can increase the anticancer activity of 4(3H)-quinazolone derivatives (Fig. 2).12,15However, research on 4(3H)-quinazolone derivatives with different substituents at position 3 (differentN-methylenamino groups/N–NCreated by potrace 1.16, written by Peter Selinger 2001-2019C–R), 6-chloro, and 2-phenyl group is still limited, especially in terms of anticancer activity. Therefore, the study aimed to synthesize 3-arylmethylenamino-2-phenyl-4(3H)-quinazolone derivatives for anticancer activity screening, as well as molecular docking andin silicoADMET studies of potential active derivatives to create a scientific basis for the development of new cancer drugs.

The first step of the procedure involved dehydration and cyclization using 5-chloroanthranilic acid and benzoyl chloride as starting materials. Our effort resulted in a relatively simple procedure with a high yield of 85%. Notably, this stage requires an anhydrous environment and precise temperature control. Due to the moisture-sensitive nature of benzoyl chloride, anhydrous pyridine obtained by distillation was chosen as the solvent. This exothermic reaction generates the temperature-sensitive 4H-benzo[d][1,3]-oxazin-4-one (Q0), which demands a low reaction temperature. Subsequently, purified Q0 can only be dried under vacuum at a temperature below 40 °C.

In the second step, Q0 reacts with hydrazine hydrate, in the presence of sulfuric acid and PPA as cyclization and dehydration catalysts, forming 3-amino-6-chloro-2-phenyl-4(3H)-quinazolone (1). The reaction proceeded for approximately 3–4 hours, yielding 66%. In other studies, the absence of 6-chloro substitution led to higher yields (around 88%), even in the absence of cyclization catalysts.19This suggests that the introduction of a 6-chloro substituent interferes with the cyclization process.

Finally, from 3-amino-6-chloro-2-phenyl-4(3H)-quinazolone (1), imine formation was carried out, yielding 20 derivatives (2–21) with good yields (66–90%) (Table 1). Imine formation is generally conducted in acidic solvents (glacial acetic acid, ethanol,etc.) (Scheme 1). Meanwhile, 3-amino-6-chloro-2-phenyl-4(3H)-quinazolone (1) is unstable in acidic aqueous solution at high temperatures. Attempts have been made to seek an appropriate condition to maintain the integrity of the quinazolinone ring while forming the imine derivatives. Absolute ethanol was selected as the solvent, and the reaction was done at 80 °C for 1–3 hours. The reaction time and yield depended on the type, number, and position of substituents on the phenyl ring. Higher yields and shorter reaction times were observed with derivatives containing electron-donating groups, two substituents, andpara- orortho-substitutions.

Spectra investigation by FT-IR, MS,1H NMR, and13C NMR has confirmed the molecular structure of the synthesized compounds Q0, 1–21. Stretching frequency in FT-IR spectra within the region 3380–3450 cm−1due to CCreated by potrace 1.16, written by Peter Selinger 2001-2019N was observed, and that between 1660–1692 cm−1indicated CCreated by potrace 1.16, written by Peter Selinger 2001-2019O of quinazolinone. In several mass spectra, ion peaks with a relative ratio of 7 : 3 could be encountered, which are aligned with the presence of chlorine (35Cl and37Cl in a ratio of 3 : 1) in all structures. Additionally, ion peaks of 274m/zhave been regularly seen in curated MS spectra. The structure with a molecular mass of 274m/zwas predicted as inFig. 3, given that the CCreated by potrace 1.16, written by Peter Selinger 2001-2019N imine and N3–C4bonds are less stable and more likely to cleave during the fragmentation.

The IC50results (μM) on two cancer cell lines (RD – rhabdomyosarcoma cell line and MDA-MB-231 – human breast cancer cell line) and one normal cell line (LLC-PK1 – pig kidney-derived cell line) are presented inTable 2. The comparison of IC50values of the 3-methylenamino-4(3H)-quinazolone derivatives with potential anticancer activity against the cancer cell lines RD, MDA-MB-231, and LLC-PK1 compared to the reference drug Paclitaxel (PTX) is shown in boldface.

Mean ± SD, PTX – paclitaxel, RD – rhabdomyosarcoma cell line, MDA-MB-231 – human breast cancer cell line, LLC-PK1 – pig kidney-derived cell line.

Compounds 2–4 and 8–21 exhibited weak to moderate cytotoxic activity against two cancer cell lines RD (38.59–430.03 μM) and MDA-MB-231 (21.61–328.90 μM), compared to the reference drug PTX (IC50RD = 0.58 μM and IC50MDA-MB-231 = 0.04 μM). Compound 5 (2-chloro-6-fluorobenzylidene) exhibited good cytotoxic activity against RD with an IC50value of 14.65 μM but exhibited weak cytotoxic activity against MDA-MB-231 with an IC50value of 147.70 μM. In contrast, compounds 6 (benzo[d][1,3]dioxol-5-ylmethylene) and 7 (4-bromo-2-hydroxybenzylidene) showed good cytotoxic activity against MDA-MB-231 with IC50values of 10.62 and 8.79 μM, respectively. However, these two compounds exhibited weak cytotoxic activity (IC50= 50–55 μM) against the RD cell line. Notably, three potential compounds 5, 6, and 7 exhibited weak cytotoxic activity against the normal cell line LLC-PK1 (IC50= 34.82–60.18 μM), while the reference drug PTX exhibited strong cytotoxicity against LLC-PK1 with an IC50of 1.31 μM. These results showed that potential compounds 5, 6, and 7 showed selective cytotoxic activity on cancer cell lines. Therefore, these compounds are promising for further research for the development of new cancer therapeutic agents.

Several 6-substituted 4(3H)-quinazolone and chloro-4(3H)-quinazolone derivatives have been demonstrated to have potential cytotoxic activity. The 6-methyl-4(3H)-quinazolone derivative with 2-thio (amide) and 3-phenyl substituents showed IC50values of approximately 20 μg mL−1and exhibited stronger inhibitory activity against HT-29 (72%) and SW620 (63.3%) cell lines than fluorouracil (34.1% for HT-29 and 57.3% for SW620).13Meanwhile, the 6-methyl-4(3H)-quinazolone derivative with 2-thio (ester) and 3-(4-fluorophenyl) substituents exhibited strong cytotoxic activity against A549, MDA-MB231, and HeLa cell lines with IC50values of 0.57, 1.19, and 1.26 mM, respectively.14In addition, the 7-chloro-4(3H)-quinazolone derivative showed antitumor activity against murine leukemia L-1210 cell line and human leukemia K-562 and HL-60 cell lines.10The 6-fluoro-4(3H)-quinazolone derivative with 2-methyl and 3-phenyl substituents showed potential antitumor activity against MCF-7 (IC50= 3.42 μM) and NCI (IC50= 2.51 μM) cell lines.11Furthermore, the 6-fluoro-4(3H)-quinazolone derivative with a 2,3-diphenyl substituent showed potential antitumor activity with high percentage inhibition against MCF-7 (97.5%) and HepG2 (94.6%) cell lines at a concentration of 25 μmol for 48 h.12The present study also demonstrated that 6-chloro-4(3H)-quinazolone derivatives have good and selective anticancer activity. The attachment of small substituents (halogen) at position 6 and large substituents (aromatic) at position 3 in the 4(3H)-quinazolone scaffold may be responsible for the potential and selective anticancer activity of these derivatives.

Three potential compounds 5, 6, and 7 showed the physicochemical properties agreed with the directions of drug-likeness rules, including Lipinski (MW ≤ 500, MLOGP ≤ 4.15,nHA ≤ 10, andnHD ≤ 5), Veber (nRot ≤ 10 and TPSA ≤ 140), and Egan (WLOGP ≤ 5.88 and TPSA ≤ 131.6), similar to reference drug Gefitinib (GEF), while reference drug paclitaxel (PTX) did not show agreement with all drug-likeness rules. In particular, compound 6 also exhibited physicochemical properties agreed with many drug-likeness rules such as Lipinski, Veber, Egan, Ghose (160 ≤ MW ≤ 480, −0.4 ≤ WLOGP ≤ 5.6, 40 ≤ MR ≤ 130, and 20 ≤ atoms ≤ 70), and Muegge (200 ≤ MW ≤ 600, −2 ≤ XLOGP ≤ 5, TPSA ≤ 150, num. Rings ≤ 7, num. Carbon > 4, num. Heteroatoms > 1,nRot ≤ 15,nHA ≤ 10, andnHD ≤ 5) compared to GEF (Table 3).

According to literature report, PTX – paclitaxel, GEF – Gefitinib, Caco-2 permeability (optimal: higher than −5.15 log unit), MDCK permeability (low permeability: < 2 × 10−6cm s−1, medium permeability: 2–20 × 10−6cm s−1, high passive permeability: >20 × 10−6cm s−1), PAMPA – the experimental data forPeffwas logarithmically transformed (logPeff< 2: low-permeability, logPeff> 2.5: high-permeability), Pgp – P-glycoprotein, HIA – Human Intestinal Absorption (−: ≥30%, +: <30%),F: bioavailability (+: <percent value, −: ≥percent value), PPB: Plasma Protein Binding (optimal: <90%), VD: Volume Distribution (optimal: 0.04–20 L kg−1), BBB: Blood–Brain Barrier Penetration, Fu: The fraction unbound in plasms (low: <5%, middle: 5–20%, high: >20%), CL: clearance (low: <5 mL min−1kg−1, moderate: 5–15 mL min−1kg−1, high: >15 mL min−1kg−1),T1/2(ultra-short half-life drugs: 0.5 ≤ 1 h; short half-life drugs: 1–4 h; intermediate short half-life drugs: 4–8 h; long half-life drugs: >8 h), hERG blockers (IC50≤ 10 μM or ≥50% inhibition at 10 μM were classified as hERG +, IC50> 10 μM or <50% inhibition at 10 μM were classified as hERG), DILI: Drug-Induced Liver Injury, Rat Oral Acute Toxicity (0: low-toxicity > 500 mg kg−1, 1: high-toxicity < 500 mg kg−1), FDAMDD – Maximum Recommended Daily Dose, BCF – Bioconcentration Factors, IGC50 – tetrahymena pyriformis 50 percent growth inhibition concentration, LC50FM – 96 h fathead minnow 50 percent lethal concentration, LC50DM – 48 h daphnia magna 50 percent lethal concentration. The output value is the probability of being inhibitor/substrate/active/positive/high-toxicity/sensitizer/carcinogens/corrosives/irritants (category 1) or non-inhibitor/non-substrate/inactive/negative/low-toxicity/non-sensitizer/non-carcinogens/noncorrosives/nonirritants (category 0). For the classification endpoints, the prediction probability values are transformed into six symbols: 0–0.1(−−−), 0.1–0.3(−−), 0.3–0.5(−), 0.5–0.7(+), 0.7–0.9(++), and 0.9–1.0(+++). Additionally, the corresponding relationships of the three labels are as follows:E– excellent,M– medium,P– poor.

In absorption, compounds 5, 6, and 7 showed good parameters, including Caco-2 permeability, MDCK permeability, PAMPA, Pgp-substrate, HIA (human absorption intestinal),F20%,F30%, andF50%, compared to PTX and GEF. Furthermore, the Caco-2 permeability of these compounds showed an excellent level (higher than −5.15 log unit), similar to GEF. The study results predicted that these compounds show high gastrointestinal absorption, accordingly, they may have remarkably good bioavailability after oral administration.

In distribution, compounds 5, 6, and 7 showed poor to medium parameters such as PPB (%), Fu (%), OATP1B1 inhibitor, OATP1B3 inhibitor, BCRP inhibitor, and BSEP inhibitor. These showed good plasma protein binding capacity with PPB > 90% compared to PTX compounds (PPB = 93%). However, the optimal PPB needs to be less than 90%, like the GEF. In contrast, these compounds showed two excellent parameters, including VD (optimal: 0.04–20 L kg−1) and MRP1 inhibitor. In addition, studying the BBB (Blood–Brain Barrier) permeability, compound 6 demonstrated no ability to penetrate the BBB, similar to reference drugs PTX and GEF.

In metabolism, compounds 5, 6, and 7 were predicted to be potent inhibitors of cytochrome enzymes CYP1A2, CYP2C19, CYP2C9, and CYP2C8. Additionally, compound 6 demonstrated strong inhibition of CYP3A4 as a main enzyme involved in drug metabolism, whereas compounds 5 and 7 did not exhibit inhibition of this enzyme.

In excretion, the CL (clearance) is a significant parameter in deciding dose intervals as a tool for the assessment of excretion. All active compounds and PTX showed lower CL values and were classified as low clearance levels (CL < 5 mL min−1kg−1) compared to GEF (moderate CL = 5–15 mL min−1kg−1). Therefore, compounds 5, 6, and 7 exhibited slower clearance rates, which means they require longer dosing intervals.

Finally, in toxicity, compounds 5, 6, and 7 showed poor parameters such as DILI (drug-induced liver injury), AMES toxicity, FDAMDD (maximum recommended daily dose), skin sensitization, carcinogenicity, eye irritation, human hepatotoxicity, drug-induced nephrotoxicity, drug-induced neurotoxicity, hematotoxicity, genotoxicity, and Hek293 cytotoxicity. However, these compounds did not show rat oral acute toxicity, eye corrosion, ototoxicity, RPMI-8226 immunotoxicity, and A549 cytotoxicity. Overall, the toxicity of the potential compounds was similar to that of the reference drugs PTX and GEF.

ADMETlab 3.0 and SwissADME are powerful computational tools designed to predict the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of small molecules, offering significant advantages in drug discovery such as a robust database, advanced machine learning algorithms, and integration of diverse molecular descriptors. However, limitations exist, such as the potential for inaccuracies in predictions for compounds outside the training dataset's chemical space, as seen in cases such as the mispredicted P-gp substrate status of Gefitinib. The model's dependence on specific descriptors may also miss complex biological interactions, requiring experimental validation. These limitations highlight the need for careful interpretation and additional experimental studies to ensure accuracy.

Quinazolone derivatives have been shown to have anticancer mechanisms through the inhibition of multiple tyrosine kinases.33,34Therefore, the potential derivatives were evaluated for their ability to bind to EGFR using the molecular docking study (Table 4andFig. 4). Compounds 5, 6, and 7 showed strong interactions with the EGFR target with binding affinities of −9.6, −10.1, and −9.8 kcal mol−1, respectively. In particular, these compounds were shown to have stronger binding affinities than the reference drug GEF at the EGFR active site. The aromatic groups of these compounds played a key role in binding to EGFR through multiple hydrophobic interactions.

CHB – conventional hydrogen bond (strong hydrogen bond), CarHB – carbon–hydrogen bond, GEF – Gefitinib.

In addition, compound 5 formed one halogen bond (3.05 Å, ASP855), one electrostatic π–cation interaction (4.35 Å, LYS745), and hydrophobic interactions (π–σ and π–alkyl) at amino acids LEU718, VAL726, LYS745, ALA743, and LEU844 (3.97–5.47 Å). Compound 7 established one strong hydrogen bond (2.25 Å, THR854) and hydrophobic interactions (π–σ and π–alkyl) at amino acids LEU718, VAL726, ALA743, and LYS745 (3.60–4.93 Å). Meanwhile, compound 6 only exhibited hydrophobic interactions (π–σ and π–alkyl) at amino acids LEU718, VAL726, LYS745, ALA743, and LEU844, with bond lengths ranging from 3.75 to 5.31 Å. Notably, three potential compounds exhibited interactions with amino acids LYS745, LEU718, VAL726, ALA743, and LEU844, similar to the co-crystallized ligand and reference drug GEF. Therefore, molecular docking results showed that strong EGFR inhibition may be responsible for the potent and selective anticancer activity of these compounds. However, these findings need to be confirmed byin vitrobinding studies of compounds 5, 6, and 7 to the EGFR target. Furthermore, to elucidate the mechanisms underlying the observed cytotoxicity of these compounds, further investigation into alternative molecular targets or potential off-target effects is necessary.

Benzoyl chloride, 5-chloroanthranilic acid, and hydrazine hydrate were purchased from Acros (Belgium). Benzaldehyde derivatives, other catalysts, reagents, solvents, and chemicals were obtained from Merck (Germany). Thin-layer chromatography (TLC) on silica gel plates coated with fluorescent indicator F254(Merck) was employed to monitor the completion of reactions.

The melting points of all products were recorded using the Sanyo Gallenkamp melting point apparatus. Infrared spectra were obtained on the IRAffinity-1S FT-IR spectrophotometer from Shimadzu. Synthesized substances underwent molecular characterization through mass spectrometry on an Agilent LC-MS instrument and nuclear magnetic resonance (NMR) spectroscopy recorded on Bruker Avance III 500 MHz. DMSO-d6was utilized as a solvent for all compounds. Coupling constants (J) and chemical shifts (δ) were given in Hz and ppm, respectively.

In a double-neck flask, a mixture of 5-chloroanthranilic acid (0.1 mol) and pyridine (dried, 120 mL) is dissolved and refluxed for 10–15 minutes. The mixture is then cooled to 0–5 °C for 30 minutes. Benzoyl chloride (3.2 mL) is added dropwise (1 drop per second) to the mixture, followed by continuously stirring for 2 hours. The mixture is kept cool at 0–5 °C throughout the process.

Once the reaction completion is confirmed on TLC, the reaction mixture is left at room temperature. The aqueous solution of saturated Na2CO3(100 mL) is added gradually (10 mL each time) until the pH of the mixture reaches 7. When the product crystallizes, it is filtered, washed with cold water, and dried under a vacuum to yield Q0. Synthesis yield: 85%.

Green powder, mp 194–195 °C.1H NMR (500 MHz, DMSO-d6,δppm): 8.20 (2H, d,J= 7.0 Hz, H–Ar), 8.13 (1H, s, H–Ar), 7.98 (1H, d,J= 7.5 Hz, H–Ar), 7.75 (1H, d,J= 8.0 Hz, H–Ar), 7.69–7.67 (1H, m, H–Ar), 7.63–7.61 (2H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 157.9; 156.7; 145.1; 136.6; 132.9; 132.4; 129.8; 129.0; 129.0; 127.9; 127.0; 118.6. LC-MS (m/z) [M + H]+calcd for C14H9ClNO2258.0316, found 258.0344.

A mixture of pyridine (20 mL) and Q0 (0.05 mol) is stirred for 10 minutes and refluxed at 10 °C until completely dissolves. Hydrazine hydrate (0.03 mol) is added gradually to the reaction mixture. The reaction mixture is stirred and refluxed for 2 hours until the Q0 sample disappears on the TLC plate.

Concentrated sulfuric acid and polyphosphoric acid (PPA) are subsequently added and the reaction mixture is refluxed for 2 hours. The product precipitates as white crystals. When TLC shows the completion of the reaction, the reaction mixture is then left at room temperature and cooled to 0–5 °C. An aqueous solution of 10% NaOH (25 mL) is added dropwise to neutralize the mixture to pH 8 and therefore, more crystals can be observed.

The obtained mixture is filtered, washed with cold water and dried under vacuum to yield 1. Synthesis yield: 66%.

White to beige crystal, mp 169–172 °C.1H NMR (500 MHz, DMSO-d6,δppm): 8.09 (1H, s, H–Ar), 7.82–7.81 (3H, m, H–Ar), 7.72 (1H, d,J= 3.5 Hz, H–Ar), 7.49–7.48 (3H, m, H–Ar), 5.70 (2H, s, NH2).13C NMR (125 MHz, DMSO-d6,δppm): 160.3, 156.2, 145.4, 134.5, 134.4, 130.9, 129.7, 129.6, 129.6, 127.4, 124.9, 121.2. LC-MS (m/z) [M–H]−calcd for C14H9ClN3O 270.0440, found 270.0437.

In a double-neck flask, compound 1 (0.1 mol) is dissolved and refluxed at 80 °C in ethanol absolute (30 mL). Aldehyde derivative (0.1 mol) is added and the mixture is refluxed for 1–2 hours. Once the reaction has finished, the mixture is cooled to 0–5 °C, and the product is filtered and washed with cold water. Recrystallization with the ethanol–water mixture is conducted to obtain pure products. The crystals of compounds 2–21 are dried at 60 °C under vacuum. Synthesis yield: 68–90%.

White solid, mp 238–241 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.30 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.34 (2H, d,J= 8.5 Hz, H–Ar), 8.19 (1H, d,J= 2.0 Hz, H–Ar), 7.99–7.94 (3H, m, H–Ar), 7.84 (1H, d,J= 9.0 Hz, H–Ar), 7.72 (2H, d,J= 7.5 Hz, H–Ar), 7.51–7.45 (3H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 166.0, 156.6, 153.2, 149.4, 144.6, 137.7, 134.5, 134.0, 131.2, 129.6, 129.5, 129.3, 129.2, 127.3, 125.3, 123.7, 122.1. LC-MS (m/z) [M + H]+calcd for C21H14ClN4O3405.0749, found 405.0792.

White solid, mp 225–226 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.13 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.17 (1H, d,J= 2.0 Hz, H–Ar), 7.93–7.94 (2H, m, H–Ar), 7.82 (1H, d,J= 8.5 Hz, H–Ar), 7.78 (1H, d,J= 8.5 Hz, H–Ar), 7.70–7.68 (3H, m, H–Ar), 7.52–7.45 (3H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 165.8, 156.7, 144.7, 134.9, 134.6, 134.0, 132.7, 131.9, 131.3, 131.2, 129.7, 129.6, 129.4, 127.9, 127.4, 125.4, 122.1. LC-MS (m/z) [M + H]+calcd for C21H13Cl3N3O 428.0119, found 428.0130.

White solid, mp 207–208 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.04 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.17 (1H, d,J= 2.5 Hz, H–Ar), 7.93 (1H, dd,J= 8.5, 2.5 Hz, H–Ar), 7.83–7.78 (3H, m, H–Ar), 7.69 (2H, d,J= 7.0 Hz, H–Ar), 7.50–7.43 (3H, m, H–Ar), 7.37–7.34 (2H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 168.5, 156.9, 153.5, 145.1, 134.8, 134.2, 131.4, 131.2, 131.1, 130.0, 129.9, 129.7, 128.8, 127.7, 125.6, 122.3, 116.4, and 116.2 (JC–F= 25.0 Hz). LC-MS (m/z) [M + H]+calcd for C21H14ClFN3O 378.0804, found 378.0814.

White solid, mp 205–208 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.31 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.20 (1H, d,J= 2.0 Hz, H–Ar), 7.93 (1H, dd,J= 8.5, 2.5 Hz, H–Ar), 7.81 (1H, d,J= 8.5 Hz, H–Ar), 7.69 (2H, d,J= 7.5 Hz, H–Ar), 7.63–7.59 (1H, m, H–Ar), 7.49–7.37 (4H, m, H–Ar), 7.35 (1H, dd,J= 9.5, 9.5 Hz, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 164.2, 156.7, 153.4, 145.0, 135.0, 134.8, 134.3, 134.2, 131.4, 129.9, 129.8, 129.7, 127.6, 126.6, 125.8, 122.5, 118.7, 116.0, 115.9, and 115.8 (JC–F= 12.5 Hz). LC-MS (m/z) [M + H]+calcd for C21H13Cl2FN3O 412.0414, found 412.0441.

White solid, mp 215–217 °C.1H NMR (500 MHz, DMSO-d6,δppm): 8.86 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.16 (1H, d,J= 2.5 Hz, H–Ar), 7.92 (1H, dd,J= 8.5, 2.5 Hz, H–Ar), 7.80 (1H, d,J= 8.5 Hz, H–Ar), 7.69–7.68 (2H, m, H–Ar), 7.48–7.43 (3H, m, H–Ar), 7.27 (1H, dd,J= 8.0, 2.5 Hz, H–Ar), 7.18 (1H, d,J= 1.0 Hz, H–Ar), 7.05 (1H, d,J= 8.0 Hz, H–Ar), 6.12 (2H, s, –OCH2O–).13C NMR (125 MHz, DMSO-d6,δppm): 169.0, 156.9, 153.5, 151.4, 148.1, 145.1, 134.7, 134.3, 131.3, 129.9, 129.8, 129.7, 127.7, 126.6, 126.4, 125.5, 122.3, 108.6, 105.5, 102.0. LC-MS (m/z) [M + H]+calcd for C22H15ClN3O3404.0797, found 404.0742.

White to light yellow solid, mp 247–248 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.21 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.17 (1H, d,J= 2.5 Hz, H–Ar), 7.92 (1H, dd,J= 8.5, 2.5 Hz, H–Ar), 7.81 (1H, d,J= 9.0 Hz, H–Ar), 7.68 (2H, d,J= 7.0 Hz, H–Ar), 7.60–7.58 (1H, m, H–Ar), 7.54 (1H, dd,J= 9.0, 2.5 Hz, H–Ar), 7.51–7.45 (3H, m, H–Ar), 6.92 (1H, d,J= 9.0 Hz, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 164.4, 157.9, 157.0, 153.6, 145.0, 136.4, 134.7, 134.4, 131.3, 129.9, 129.8, 129.6, 129.2, 127.7, 125.6, 122.5, 120.4, 119.1, 110.5. LC-MS (m/z) [M + H]+calcd for C21H14BrClN3O2453.9952, found 453.9970; [M–H]−calcd for C21H12BrClN3O2451.9807, found 451.9809.

White solid, mp 220–221 °C.1H NMR (500 MHz, DMSO-d6,δppm): 8.65 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.15 (1H, d,J= 2.5 Hz, H–Ar), 7.90 (1H, dd,J= 8.5, 2.5 Hz, H–Ar), 7.80 (1H, d,J= 8.5 Hz, H–Ar), 7.68 (2H, d,J= 7.0 Hz, H–Ar), 7.53 (2H, d,J= 9.0 Hz, H–Ar), 7.47–7.41 (3H, m, H–Ar), 6.74 (2H, d,J= 8.5 Hz, H–Ar), 3.01 (6H, s, –N(CH3)2).13C NMR (125 MHz, DMSO-d6,δppm): 169.8, 157.2, 153.7, 153.1, 145.2, 134.4, 131.1, 130.4, 129.7, 127.4, 125.4, 122.4, 118.8, 111.5. LC-MS (m/z) [M + H]+calcd for C23H20ClN4O 403.1320, found 403.1334.

White to beige solid, mp 255–257 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.78 (1H, s, –OH), 8.92 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.17 (1H, s, H–Ar), 7.92 (1H, d,J= 8.5 Hz, H–Ar), 7.81 (1H, d,J= 9.0 Hz, H–Ar), 7.68 (2H, d,J= 7.5 Hz, H–Ar), 7.49–7.44 (3H, m, H–Ar), 7.39–7.32 (1H, m, H–Ar), 7.15–7.12 (2H, m, H–Ar), 6.97 (1H, d,J= 8.5 Hz, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 170.2, 157.7, 153.4, 145.1, 134.7, 134.2, 133.3, 131.3, 130.2, 130.0, 129.8, 129.7, 127.7, 125.6, 120.4, 120.0, 113.9. LC-MS (m/z) [M + H]+calcd for C21H15ClN3O2376.0847, found 376.0839.

White to beige solid, mp 210–212 °C.1H NMR (500 MHz, DMSO-d6,δppm): 8.78 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.15 (1H, d,J= 2.0 Hz, H–Ar), 7.91 (1H, dd,J= 9.0, 2.5 Hz, H–Ar), 7.80 (1H, d,J= 8.5 Hz, H–Ar), 7.70 (2H, d,J= 7.5 Hz, H–Ar), 7.47–7.43 (3H, m, H–Ar), 7.20 (1H, s, H–Ar), 7.17 (1H, d,J= 8.0 Hz, H–Ar), 6.88 (1H, d,J= 8.0 Hz, H–Ar), 3.97 (2H, q,J= 7.0 Hz, –CH2–), 1.31 (3H, t,J= 7.0 Hz, –CH3).13C NMR (125 MHz, DMSO-d6,δppm): 169.2, 157.0, 153.6, 151.7, 147.1, 145.1, 134.6, 134.3, 131.2, 129.8, 129.8, 127.6, 125.5, 124.3, 123.4, 122.4, 115.6, 111.6, 63.8, 14.5. LC-MS (m/z) [M + H]+calcd for C23H19ClN3O3420.1109, found 420.1125.

White to beige solid, mp 198–200 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.45 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.19 (1H, d,J= 2.0 Hz, H–Ar), 7.93 (1H, dd,J= 9.0, 2.5 Hz, H–Ar), 7.84–7.80 (2H, m, H–Ar), 7.69 (2H, d,J= 7.0 Hz, H–Ar), 7.66 (1H, d,J= 8.5 Hz, H–Ar), 7.53–7.45 (4H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 163.1, 156.8, 153.3, 144.6, 137.6, 135.5, 134.4, 134.1, 131.2, 129.6, 129.5, 129.4, 129.3, 128.7, 128.6, 127.9, 127.3, 125.4, 122.2. LC-MS (m/z) [M + H]+calcd for C21H13Cl3N3O 428.0119, found 428.0141.

White to beige solid, mp 223–224 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.46 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.21 (1H, d,J= 2.5 Hz, H–Ar), 7.93 (1H, dd,J= 2.5, 8.5 Hz, H–Ar), 7.82 (1H, d,J= 8.5 Hz, H–Ar), 7.68–7.71 (3H, m, H–Ar), 7.58–7.64 (2H, m, H–Ar), 7.46–7.52 (3H, m, H–Ar), 7.43–7.40 (1H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 164.6, 164.4, 156.7, 153.3, 148.4, 144.7, 134.7, 134.4, 134.1, 133.5, 131.1, 129.9, 129.7, 129.5, 129.4, 129.3, 127.5, 127.4, 127.3, 125.4, 122.2, 119.2. LC-MS (m/z) [M + H]+calcd for C21H14Cl2N3O 394.0509, found 394.0513.

White to beige powder, mp 176–177 °C.1H NMR (500 MHz, DMSO-d6,δppm): 8.88 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.16 (1H, d,J= 2.0 Hz, H–Ar), 7.91 (1H, dd,J= 9.0, 2.5 Hz, H–Ar), 7.81 (1H, d,J= 9.0 Hz, H–Ar), 7.71 (2H, d,J= 7.0 Hz, H–Ar), 7.49–7.43 (3H, m, H–Ar), 7.30 (1H, d,J= 8.0 Hz, H–Ar), 7.24 (1H, s, H–Ar), 7.07 (1H, d,J= 8.0 Hz, H–Ar), 3.83 (3H, s, –OCH3), 3.71 (3H, s, –OCH3).13C NMR (125 MHz, DMSO-d6,δppm): 168.2, 156.9, 153.5, 152.8, 149.0, 144.9, 134.3, 134.2, 131.1, 129.5, 129.5, 129.5, 127.3, 125.2, 124.8, 123.8, 122.2, 111.7, 109.9; 55.60, 55.40. LC-MS (m/z) [M–H]−calcd for C23H17ClN3O3418.0964, found 418.0973.

White to beige solid, mp 184–186 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.18 (1H, s, H–Ar), 8.87 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.75–8.74 (1H, dd,J= 4.5, 1.0 Hz, H–Ar), 8.18 (1H, d,J= 2.0, H–Ar), 8.07 (1H, d,J= 8.0 Hz, H–Ar), 7.93 (1H, dd,J= 8.5, 2.0 Hz, H–Ar), 7.82 (1H, d,J= 8.5 Hz, H–Ar), 7.71 (2H, d,J= 7.0, H–Ar), 7.55–7.44 (4H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 166.9, 156.9, 153.5, 153.1, 149.9, 145.0, 134.9, 134.9, 134.2, 131.4, 130.0, 129.9, 129.7, 128.2, 127.7, 125.6, 124.3, 122.3. LC-MS (m/z) [M + H]+calcd for C20H14ClN4O 361.0851, found 361.0860.

White to beige solid, mp 214–216 °C.1H NMR (500 MHz, DMSO-d6,δppm): 8.85 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.16 (1H, d,J= 2.5 Hz, H–Ar), 7.99 (1H, s, H–Ar), 7.92 (1H, dd,J= 9.0, 2.5 Hz, H–Ar), 7.80 (1H, d,J= 9.0 Hz, H–Ar), 7.67 (2H, d,J= 7.0 Hz, H–Ar), 7.50–7.44 (3H, m, H–Ar), 7.25 (1H, d,J= 3.5 Hz, H–Ar), 6.75–6.74 (1H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 157.7, 156.7, 148.4, 147.7, 147.2, 146.4, 134.4, 134.2, 129.8, 129.6, 129.5, 129.4, 128.3, 127.7, 127.4, 125.3, 125.1, 122.1, 119.4, 112.5, 112.4. LC-MS (m/z) [M + H]+calcd for C19H13ClN3O2350.0691, found 350.1725.

White solid, mp 227–229 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.31 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.49 (1H, s, H–Ar), 8.40 (1H, d,J= 8.5 Hz, H–Ar), 8.18 (1H, d,J= 2.5 Hz, H–Ar), 8.15 (1H, d,J= 7.5 Hz, H–Ar), 7.94 (1H, dd,J= 8.5, 2.5 Hz, H–Ar), 7.84–7.79 (2H, m, H–Ar), 7.71 (2H, d,J= 7.0 Hz, H–Ar), 7.52–7.45 (3H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 166.1, 156.8, 153.4, 148.1, 144.7, 134.6, 134.1, 133.8, 131.3, 130.6, 129.7, 129.6, 129.4, 127.5, 126.4, 125.4, 122.4, 122.1. LC-MS (m/z) [M + H]+calcd for C21H14ClN4O3405.0749, found 405.0758.

White solid, mp 218–219 °C.1H NMR (500 MHz, DMSO-d6,δppm): 8.87 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.16 (1H, s, H–Ar), 7.91 (1H, dd,J= 8.5, 1.5 Hz, H–Ar), 7.81 (1H, d,J= 8.5 Hz, H–Ar), 7.69–7.65 (4H, m, H–Ar), 7.47–7.42 (3H, m, H–Ar), 7.03 (2H, d,J= 8.5 Hz, H–Ar), 4.11 (2H, q,J= 7.0 Hz, H–Ar), 1.34 (3H, t,J= 7.0 Hz, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 169.7, 169.6, 162.2, 159.6, 157.0, 145.1, 138.8, 134.7, 134.3, 131.3, 130.6, 129.8, 129.7, 127.7, 125.5, 124.4, 122.4, 115.0, 63.6, 14.5. LC-MS (m/z) [M + H]+calcd for C23H19ClN3O2404.1160, found 404.1186.

White solid, mp 178–179 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.02 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.17 (1H, d,J= 2.5 Hz, H–Ar), 7.93 (1H, dd,J= 9.0, 2.5 Hz, H–Ar), 7.82 (1H, d,J= 9.0 Hz, H–Ar), 7.70 (2H, d,J= 6.5 Hz, H–Ar), 7.50–7.41 (4H, m, H–Ar), 7.30 (1H, d,J= 8.5 Hz, H–Ar), 7.23 (1H, s, H–Ar), 7.17–7.15 (1H, m, H–Ar), 3.75 (3H, s, –OCH3).13C NMR (125 MHz, DMSO-d6,δppm): 169.1, 159.5, 156.9, 153.6, 145.0, 134.8, 134.3, 133.6, 131.4, 130.3, 129.9, 129.9, 129.7, 127.7, 125.6, 122.4, 121.5, 118.8, 112.6, 55.2. LC-MS (m/z) [M + H]+calcd for C22H17ClN3O2390.1004, found 390.1016.

White to beige solid, mp 211–213 °C.1H NMR (500 MHz, DMSO-d6,δppm): 10.38 (1H, s, –OH), 9.18 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.17 (1H, d,J= 2.5 Hz, H–Ar), 7.92 (1H, dd,J= 8.5, 2.0 Hz, H–Ar), 7.81 (1H, d,J= 8.5 Hz, H–Ar), 7.69 (2H, d,J= 7.0 Hz, H–Ar), 7.55 (1H, d,J= 7.0 Hz, H–Ar), 7.49–7.38 (4H, m, H–Ar), 6.94 (1H, d,J= 2.0 Hz, H–Ar), 6.89–6.86 (1H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 167.2, 158.6, 157.0, 153.6, 145.1, 134.7, 134.4, 131.3, 129.9, 129.8, 129.6, 129.1, 128.2, 127.8, 125.6, 122.5, 119.6, 118.0, 116.7. LC-MS (m/z) [M + H]+calcd for C21H15ClN3O2376.0847, found 376.0839; [M–H]−calcd for C21H13ClN3O2374.0702, found 374.0696.

White to beige solid, mp 240–242 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.43 (1H, s, –OH), 8.77 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.15 (1H, d,J= 2.5 Hz, H–Ar), 7.91 (1H, dd,J= 8.5, 2.0 Hz, H–Ar), 7.81 (1H, d,J= 8.5 Hz, H–Ar), 7.67 (2H, d,J= 6.5 Hz, H–Ar), 7.47–7.43 (3H, m, H–Ar), 7.16 (2H, d,J= 8.0 Hz, H–Ar), 7.03 (1H, d,J= 8.0 Hz, H–Ar), 3.83 (3H, s, –OCH3).13C NMR (125 MHz, DMSO-d6,δppm): 170.0, 156.9, 153.5, 152.0, 146.9, 145.1, 134.6, 134.3, 131.2, 129.9, 129.8, 129.7, 127.6, 125.5, 124.7, 123.0, 122.3, 113.1, 111.8, 55.7. LC-MS (m/z) [M + H]+calcd for C22H17ClN3O3406.0953, found 406.0964; [M–H]−calcd for C22H15ClN3O3404.0807, found 404.0798.

White needle-shaped crystal, mp 184–185 °C.1H NMR (500 MHz, DMSO-d6,δppm): 9.03 (1H, s, –CHCreated by potrace 1.16, written by Peter Selinger 2001-2019N), 8.17 (1H, d,J= 2.5 Hz, H–Ar), 7.93 (1H, dd,J= 9.0, 2.5 Hz, H–Ar), 7.82 (1H, d,J= 9.0 Hz, H–Ar), 7.73–7.69 (4H, m, H–Ar), 7.61–7.58 (1H, m, H–Ar), 7.52–7.43 (5H, m, H–Ar).13C NMR (125 MHz, DMSO-d6,δppm): 169.8, 156.9, 153.5, 145.0, 134.7, 134.2, 132.7, 132.1, 131.3, 129.9, 129.8, 129.7, 129.1, 128.6, 127.7, 125.6, 122.3. LC-MS (m/z) [M + H]+calcd for C21H15ClN3O 360.0898, found 360.0899.

The cytotoxic activity of the quinazolinone derivatives was evaluated against two cancer cell lines (RD and MDA-MB-231) and one normal cell line (LLC-PK1) using the methylthiazolyl tetrazolium (MTT) method, conducted according to the MTT assay protocol. PTX was used as the positive control. The assay detects the reduction of yellow tetrazolium by metabolically active cells to purple formazan, which is measured using spectrophotometry. The cell lines were seeded into 96-well plates at a density of 5000 cells per well and incubated at 37 °C in 5% CO2for 24 h with growth media consisting of 2 mMl-glutamine, 100 IU mL−1penicillin, 100 μg mL−1streptomycin, Eagle's minimum essential medium, and 10% fetal calf serum. After that, a series of concentrations of the tested compounds and the reference drug PTX in DMSO was added to each well of the plate and incubated for 72 h. The 10 μL fresh solution of MTT reagent was added to each well, and the plate was incubated in a CO2incubator at 37 °C for 4 h until a purple precipitate appeared. Finally, the cells were solubilized in ethanol, and their optical density was recorded at 570 nm.35,36The percent of proliferation inhibition was calculated using the following formula:At= absorption of test compound,Ab= absorption of blank,Ac= absorption of control.

In summary, twenty 3-methylenamino-4(3H)-quinazolone derivatives have been designed, synthesized, and screened for anticancer activity as well as molecular docking andin silicoADMET studies. These derivatives were synthesized with good yields (66–90%) in a short time (1–2 h) using the classical reflux method. Additionally,in vitroresults demonstrated that compound 5 exhibited good cytotoxic activity against the RD cell line (IC50= 14.65 μM), while compounds 6 and 7 showed good cytotoxic activity against the MDA-MB-231 cell line with IC50values of 10.62 and 8.79 μM, respectively. In particular, these compounds exhibited weak cytotoxic activity against the LLC-PK1 normal cell line compared to paclitaxel. This result demonstrated their selective anticancer properties. Furthermore, molecular docking predicted that compounds 5, 6, and 7 showed a strong binding affinity from −9.6 kcal mol−1to −10.1 kcal mol−1with the crucial residue of the EGFR target that resembles the co-crystallization ligand and reference drug Gefitinib. The obtainedin silicoADMET results suggested that these potent derivatives possess a good ADMET profile. This work paved the way for the synthesis of more potent compounds based on 3-methyleneamino-4(3H)-quinazolone scaffolds and explored their various biological activities as well as their mechanism of action.